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Abstract
Background A syndrome of young-onset diabetes mellitus associated with microcephaly, epilepsy and intellectual
disability caused by mutations in the tRNA methyltransferase 10 homologue A (TRMT10A) gene has recently been
described.
Case report We report two siblings from the fourth family reported to have diabetes mellitus as a result of a TRMT10A
mutation. A homozygous nonsense mutation p.Glu27Ter in TRMT10A was identified using targeted next-generation
sequencing and confirmed by PCR/Sanger sequencing. Diabetes was diagnosed while the subjects were in their 20s and
was characterized by insulin resistance. Epilepsy and intellectual disability were features in common. Mild microcephaly
was present at birth but their final head circumferences were normal.
Conclusion Our report provides independent confirmation of the role of TRMT10A mutations in this syndrome and
expands its phenotypic description. TRMT10A sequencing should be considered in children or adults with young-onset
diabetes who have a history of intellectual disability, microcephaly and epilepsy. This report also shows the advantages
of using a targeted panel to identify previously unsuspected monogenic diabetes among young-onset non-insulin-
dependent diabetes in the absence of obesity and autoimmunity.
Diabet. Med. 33, e21–e25 (2016)
Introduction
Recently, a novel syndrome of young-onset diabetes
mellitus or abnormal glucose homeostasis associated with
microcephaly, epilepsy and intellectual disability attribu-
table to homozygous mutations in the tRNA methyltrans-
ferase 10 homologue A (TRMT10A) gene was reported in
two families [1,2]. In another report, an individual with
TRMT10A deletion with failure to thrive, delayed
puberty, intellectual disability and diabetes was described
[3].
In the present paper, we report two siblings with young
adult-onset diabetes, associated with intellectual disability,
microcephaly in childhood and epilepsy, as a result of a third
homozygous mutation in the TRMT10A gene.
Case report
The proband was the first child born to non-consanguineous
white parents (Fig. 1). The pregnancy was uneventful and the
childwas born at termwithout postnatal problems. The child’s
birth weight was 2700 g (-1.6 SD), length was 47.2 cm (-1.7 SD)
and she hadmildmicrocephaly [head circumference32.5cm(-2
SD)]. She had mild intellectual disability, first noticed when she
attended primary school, but other developmental milestones
were normal. She was diagnosed with grand-mal epilepsy at 5
years old. MRI of the brain was normal. Her head circumfer-
ence was 49 cm (-2 SD) at 6 years 9months old but improved to
50.3 cm (-1.3 SD) at 9 years 5 months old. Her final head
circumference was normal at 53.1 cm (-1.3 SD). Growth in
terms of height and weight was normal. Diabetes was
diagnosed at 24 years old [plasma glucose 25.1 mmol/l, HbA1c
142 mmol/mol (15.1%), BMI 24.2 kg/m2 (weight 62.8 kg,
height 1.61m)]. Shehada buffalo humpbut features of familial
partial lipodystrophy and Cushing’s syndrome were absent.
Shedidnothaveketoacidosis andwasnegative for antiglutamic
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aciddecarboxylase andanti-islet antigen-2 antibodies. Shewas
treatedwith insulin (1.0–1.2 units/kg/day) andmetformin.Her
HbA1c ranged from 50 to 85 mmol/mol (6.7 to 9.9%). Fasting
C-peptide, measured 8 years after diagnosis, was detectable at
540 pmol/l. She had severe preproliferative retinopathy at 4
months after diagnosis, suggestive of long-standing hypergly-
caemia, but has no nephropathy or neuropathy to date.
The proband’s brother was born at 43 weeks gestation.
Microcephaly was described at birth but the head circum-
ference was not recorded. His birth weight was 3274 g (-0.7
SD). He started walking at 3 years old and could first speak in
phrases at 6 years old. He attended special school because of
intellectual disability. Epilepsy was diagnosed at 4 years old
and he had delayed puberty. His final head circumference
was normal at 54.5 cm (-0.4 SD). Diabetes was diagnosed
when screened at 28 years using a 75-g oral glucose tolerance
test (OGTT; plasma glucose 8.8 mmol/l at 0 min, 19.8 mmol/l
at 120min). HisHbA1c level was 60mmol/mol (7.6%) and his
BMI was 28.4 kg/m2 (weight 89.0 kg, height 1.77 m). Physical
examination was normal. Fasting C-peptide level was 1000
pmol/l. The HbA1c level improved to 43 mmol/mol (6.1%)
after 3 months of metformin therapy.
Neither the proband nor her brother had spontaneous
hypoglycaemia. Both of them had mildly elevated LDL
cholesterol and normal liver function tests. Skeletal surveys
showed attenuated frontal skull vaults in both of them, in
keeping with the history of microcephaly, but epiphyseal
dysplasia was absent. Both their parents had normal heights,
head circumferences and BMI, no epilepsy, intellectual disabil-
ity, diabetes or prediabetes (normal OGTT results). Their
maternal grandparents, now deceased, had Type 2 diabetes
diagnosed after their 60s; their genotypes are not known.
All subjects provided written informed consent for blood
sample collection and studies, as well as for the writing and
publication of this report. The proband had participated in
the UNITED (Using Pharmacogenetics to Improve Treatment
in Early-Onset Diabetes) study when analysis of her HNF1A
and HNF4A genes did not identify any mutation. Testing for
mutations in all of the known or putative monogenic
diabetes genes as part of the study was undertaken using
targeted next-generation sequencing as previously described
[4]. Sequencing was performed with a HiSeq2000 system
(Illumina, San Diego, CA, USA; 48 samples per lane) and 100
bp paired end reads. Mutation confirmation was performed
by PCR/Sanger sequencing. Subsequently, samples of the
proband’s brother and parents were tested for TRMT10A
mutation using PCR/Sanger sequencing. Plasma glucose and
insulin was measured in the proband’s brother and parents at
0, 30, 60, 90 and 120 min in the 75-g OGTT. As a
comparator, surrogate indices for insulin resistance and
b-cell function of the brother were compared with the means
of four age- and BMI-matched healthy control subjects.
Results
Metabolic studies
The OGTT results of the proband’s brother are shown in
Fig. 2. He was newly diagnosed with diabetes. The findings
were suggestive of insulin resistance [Matsuda index 1.46;
FIGURE 1 Family pedigree. Filled symbols denote individuals with young-onset diabetes, childhood microcephaly, epilepsy and intellectual
disability; hatched symbols denote relatives with adult-onset diabetes; arrow denotes the proband. The mutation status (MN, heterozygous
TRMT10A p.Glu27Ter mutation; MM, homozygous TRMT10A p.Glu27Ter mutation) is shown under each symbol.
What’s new?
 This report describes the fourth family reported to have
diabetes mellitus caused by a mutation in the
TRMT10A gene.
 In contrast to the previous families, the diabetes
mellitus in the patients we describe was diagnosed
after 20 years of age, and at diagnosis they had only
mild learning disability and epilepsy with minimal
other clinical features.
 TRMT10A sequencing should be considered in chil-
dren or adults with young-onset diabetes who have a
history of intellectual disability, microcephaly and
epilepsy.
 A targeted panel may be useful to identify previously
unsuspected monogenic diabetes among individuals
with young-onset diabetes.
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homeostatic model assessment of insulin sensitivity (HOMA
%S) 34.7][5–7] and impaired b-cell function (insulinogenic
index 0.21; disposition index 0.32; homeostatic model
assessment of b-cell function (HOMA%b) 63.6][6–8]. For
comparison, the mean (SD) values for the four age- and BMI-
matched controls were: Matsuda index 14.2 (9.5); HOMA%
S 165 (114); insulinogenic index 0.99 (0.52); disposition
index 12.70 (11.85); HOMA%b 106 (51). The Matsuda
indices of the father and mother were 8.86 and 10.49,
respectively.
Genetic studies
A homozygous G to T transition in exon 2 of gene
TRMT10A at nucleotide position 79 of the coding sequence
was identified in the proband. This variant replaces a
glutamic acid residue with a premature termination codon
at position 27 of the polypeptide (NM_001134665.1:
c.79G>T; p.Glu27Ter). Mutations of other monogenic dia-
betes genes were not detected. This mutation was confirmed
on Sanger sequencing to be homozygous in the proband and
her brother, and heterozygous in both parents.
Discussion
Igoillo-Esteve et al. [1] first described a new syndrome of
young-onset diabetes, microcephaly, intellectual disability
and epilepsy attributable to a homozygous nonsense muta-
tion p.Arg127Ter in TRMT10A in a consanguineous family
of Moroccan origin, with three out of nine children affected.
Gillis et al. [2] identified a missense mutation p.Gly206Arg
in TRMT10A in three out of 12 siblings born to
non-consanguineous parents from a small, inbred Jewish
community in Uzbekistan. More recently, Zung et al. [3]
described an individual with TRMT10A deletion with failure
to thrive, delayed puberty, intellectual disability and dia-
betes. In the present paper, we report the eighth and ninth
individual from the fourth family known to have this
syndrome as a result of a TRMT10A mutation.
The clinical characteristics of our patients are compared
with previous reports in Table 1. Diabetes caused by
TRMT10A mutations was diagnosed between the ages of 9
and 28 years; two siblings did not have diabetes at the age of
13 and 14 years old. Interestingly, all three siblings in the
family described by Gillis et al. [2] had hypoglycaemia, as
did the individual reported by Zung et al. [3]; however, no
hypoglycaemia was reported in our patients or in those
reported by Igoillo-Esteve et al. [1]. The individuals in the
report by Gillis et al. and in our family did not have high
birth weight, suggesting intrauterine hyperinsulinaemia was
not present. Insulin resistance appeared to be the dominant
pathophysiological mechanism in our patients. This was
shown by the OGTT results in our proband’s brother which
were similar to those of the first individual described by Gillis
et al. Similarly to the individuals reported by Igoillo-Esteve
et al., the insulin requirement of our proband was quite high.
Based on the OGTT results, the parents who had heterozy-
gous mutation did not appear to be at increased risk of
diabetes.
Microcephaly was a feature in common to all the reported
cases, but the degree of severity appeared to vary. Micro-
cephaly is defined as an occipito-frontal head circumference
of >2 SD or >3 SD below the mean for age and sex [9,10].
Similar to those reported by Gillis et al. [2], our patients just
met the criteria for mild microcephaly at birth; however,
their head circumferences normalized as they grew and
achieved normal final head circumferences. This was in
contrast to the more marked microcephaly, which persisted
to adulthood in the individuals reported by Igoillo-Esteve
et al. [1] and Zung et al. [3]. All the individuals had
intellectual disability, and epilepsy was common except in
the individual reported by Zung et al. Contrary to the
previous reports, our patients did not have short stature,
although the proband did have a buffalo hump, as described
in one patient previously [1].
A homozygous nonsense mutation, p.Glu27Ter, in the
TRMT10A gene was identified in our patients. Data from the
Exome Aggregation Consortium (ExAC) browser showed
that the frequency of heterozygous TRMT10A nonsense
mutations is ~1 in 4000, and the p.Glu27Ter mutation found
in our family is the most common [11]. The family is
unaware of any close common ancestor. In humans,
TRMT10A is the orthologue most closely related to yeast
TRM10, a protein that has tRNA m1G9 methyltransferase
activity [12]. This nonsense mutation in TRMT10A at this
location is likely to result in nonsense-mediated decay and
reduced protein expression [13]. Reduced TRMT10A
FIGURE 2 Results of 75-g oral glucose tolerance test with plasma
glucose and insulin measurements in the proband’s brother, who was
previously not known to have diabetes.
ª 2015 The Authors.
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mRNA expression and TRMT10A protein deficiency was
previously shown to be the result of a p.Arg127Ter nonsense
mutation [1]. TRMT10A protein is ubiquitously present but
more abundant in human brain and pancreatic islets [1]. This
was consistent with the selected involvement of brain
(microcephaly, intellectual disability and epilepsy) and pan-
creatic islets (diabetes) in our patients. The robust insulin
secretion in our case supported the in vitro findings that
TRMT10A silencing did not appear to affect b-cell function
but may induce b-cell apoptosis [1]. The mechanism by
which the mutation is associated with insulin resistance
remains to be investigated.
In summary, the present case report provides independent
confirmation of the role of TRMT10A mutations in this
newly described syndromic form of monogenic diabetes and
expands its phenotypic description. It also highlights the
advantages of using a targeted panel to identify previously
unsuspected monogenic diabetes in young-onset non insulin-
dependent diabetes in the absence of obesity and autoimmu-
nity. Children or adults with young-onset diabetes who have
intellectual disability, microcephaly and epilepsy should
undergo genetic testing for TRMT10A mutations. Further
studies are needed to evaluate the prevalence of TRMT10A
mutations in this phenotypic group.
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